Introduction
Drug-resistant tuberculosis (TB) is still a major threat to global TB control. In 2015, there were approximately 480,000 new cases of multidrug-resistant TB (MDR-TB), an additional 100,000 cases of rifampicin-resistant TB (RR-TB), and approximately 250,000 deaths from MDR/RR-TB 1 . Successful treatment was achieved in only 52% of MDR/RR-TB patients in the 2013 cohort 1 . Despite progressive TB control worldwide, the disease burden and treatment outcomes of MDR-TB patients have remained virtually unchanged. www.e-trd.org classification of medicines, and updated recommendations for the existing conventional regimen. Until 2016, only one universal strategy had been recommended for MDR-TB. Now, we may choose between two very different strategies; the new, shorter regimen or the conventional, longer regimen. This paper will review these key changes and discuss the potential issues with the implementation of these guidelines in South Korea.
Summary of Major Changes in the 2016 Guidelines
Programmatic management of drug-resistant tuberculosis (PMDT) is a comprehensive set of strategies and activities including prevention, case detection, care and treatment, surveillance, drug management, and monitoring and evaluation of program performance. These activities should be coordinated by national TB control programs. The WHO has provided guidelines for PMDT since 2006 16 , with updates in 2008 17 and 2011 18 . The Korean guidelines have been revised in line with the update of the WHO guidelines 19, 20 . The 2016 guideline is specifically focused on the clinical aspects of MDR-TB treatment and does not cover other aspects of policy guidance. The key changes in the 2016 recommendations are as follows.
(1) The recommendation for the use of rapid diagnostics for rifampicin resistance was changed from a conditional recommendation with very low quality evidence (2011) to a strong recommendation with high evidential certainty (2016).
(2) A shorter MDR-TB treatment regimen was newly recommended under specific conditions.
(3) Medicines used in the conventional (longer) MDR-TB treatment regimen were reclassified.
(4) The optimal composition of the conventional MDR-TB treatment regimen was updated.
(5) Evidence-based recommendations on the role of surgery were newly included.
Furthermore, MDR-TB treatment is recommended for all patients with RR-TB, regardless of confirmed isoniazid resistance. Specific recommendations were made for the treatment of children with MDR/RR-TB. However, there was no change in the duration of the conventional MDR-TB regimen or in the role of new drugs (bedaquiline and delamanid). This paper will focus on the recommendations pertaining to the new classification of anti-TB drugs, the composition of the conventional regimen, and the shorter MDR-TB regimen.
New classifications of anti-TB drugs
Previous WHO guidelines classified anti-TB drugs into five groups by efficacy, experience of use, safety, and general drug class. The guidelines recommended to choose a drug in a step-down manner, from group 1 to group 5. The five-group classification originated in the 2006 guidelines 16 . Although minor modifications were made in 2008 17 , 2011 18 , and 2014 21 , the rationale for these classifications has not been changed.
In the 2016 guidelines, medicines used for the conventional MDR-TB regimen were reclassified in a hierarchical order from group A to group D (Table 1) 15 . Medicines in groups A, B, and C were classified as "core second-line agents, " while medicines in group D were classified as "add-on agents" that were not part of the core second-line agents.
Some changes were made within each classification as follows.
(1) The rankings of fluoroquinolones and second-line injectable drugs were swapped.
Fluoroquinolones are the backbone of MDR-TB treatment regimens, with bactericidal and sterilizing properties, as well as a good safety profile. Many studies have demonstrated that use of fluoroquinolones was the top predictor of favorable treatment outcome of MDR-TB patients [22] [23] [24] [25] . In contrast, the injectable drugs have only bactericidal properties and their safety profile is lower. For these reasons, fluoroquinolones were placed in group A and the injectable drugs in group B.
(2) Linezolid and clofazimine were reclassified as core second-line agents in group C, and p-aminosalicylic acid (PAS) was reclassified as an add-on agent in group D. Linezolid has demonstrated its efficacy on MDR-TB in several meta-analyses 26, 27 and two randomized controlled trials [28] [29] [30] . Clofazimine is a core drug in the shorter MDR-TB regimen and likely contributes to the sterilizing function of MDR-TB regimens, where pyrazinamide is not effective 15 . Although, consistent evidence was not found in three meta-analysis studies of the efficacy of clofazimine in MDR-TB treatment [31] [32] [33] , a single randomized controlled trial demonstrated treatment benefits associated with clofazimine 34 . Based on the growing evidences for anti-TB efficacy, linezolid and clofazimine were placed in group C. PAS has been downgraded to group D3 because its safety and tolerability is worse compare to other drugs in group 4.
(3) Clarithromycin and other macrolides are no longer recommended for MDR-TB treatment. Mycobacterium tuberculosis is intrinsically resistant to the macrolide class of antibiotics, whose efficacy in MDR-TB treatment was not demonstrated in clinical studies. Furthermore, there is a risk of QT prolongation if given in combination with other drugs such as moxifloxacin, clofazimine, bedaquiline, or delamanid. Therefore, the WHO recommended that clarithromycin and azithromycin not be included in the MDR-TB regimens.
(4) Bedaquiline and delamanid were classified in a unique group, D2. Considering the importance of treating intractable MDR-TB, both drugs were granted accelerated approval primarily based on the evidences from phase II clinical trials. Therefore, the level of evidence for efficacy and safety of both drugs remains very limited to date. In the 2016 guideline, the WHO recommended to maintain the previous interim guid-ance on the use of these medicines 35, 36 until complete phase III data were available. Both drugs have been recommended when an effective and reasonably well-tolerated MDR-TB regimen could not be composed with conventional second-line drugs.
1) Applicability in South Korea
The classification of anti-TB drugs provides a crucial clue for determining the priority of drug selection. There are some concerns about adopting the new WHO drug classifications in South Korea. The primary concern is the rankings of two repurposed drugs (linezolid and clofazimine) in group C and two new drugs (bedaquiline and delamanid) in group D2. According to the new classification, linezolid and clofazimine should be selected prior to bedaquiline and delamanid. However, until now, there has been limited clinical evidence that compares the effectiveness and safety of those agents. Some experts proposed rankings that differ from the WHO guidelines 37 . The proposed rankings indicate that linezolid, bedaquiline, and delamanid are placed in group 2, and clofazimine in group 5. The recently published endTB guidelines also suggest maintaining the existing classification of drugs until the WHO' s interim guidance on bedaquiline and delamanid is revised 38 . Despite the relatively excellent anti-TB effect, linezolid causes serious adverse effects, such as peripheral neuropathy and bone marrow suppression. Clofazimine is still doubtful as an anti-TB drug and may cause skin hyperpigmentation that can occur in almost Korean patients. Furthermore, both linezolid and clofazimine are not yet approved as anti-TB drugs in South Korea; drug cost, accessibility, and the availability of both drugs could be another barrier. Although bedaquiline and delamanid are still classified as additional agents, their priorities are likely to be changed with accumulating evidences and experiences. For these reasons, the new Korean guideline, which is published in May 2017, maintains the previous five-group classification of anti-TB drugs until more evidences are available 39 . 
Composition of the conventional regimen
The WHO also updated its recommendations on the optimal composition of the conventional regimen. The WHO recommends that the MDR-TB regimen should be composed of at least five drugs that are likely to be effective during the intensive phase, including pyrazinamide and four core secondline drugs. Core second-line drugs are added to the regimen in the following order: first a fluoroquinolone (group A), followed by a second-line injectable drug (group B), and at least two drugs from group C. If an effective regimen cannot be composed from groups A, B, and C, a drug from group D2 or D3 may be added to the regimen to bring the total number of drugs to five.
Compared to the 2011 recommendations, there are notable changes to the number of effective drugs and counting pyrazinamide based on the likely effectiveness. In 2011, the WHO recommended a regimen of at least four second-line drugs that are likely to be effective, as well as pyrazinamide (irrespective of its likely effectiveness). This recommendation was based on an individual patient meta-analysis of 9,153 cases with MDR-TB; treatment was most successful when four effective drugs were used in the intensive phase in patients with MDR-TB who were not previously treated with second-line drugs 24 .
Since the 2011 guidelines were published, there have been several cohort studies that examined the impact of number of effective drugs and pyrazinamide susceptibility on the outcome of MDR-TB. A 2012 retrospective study in Hong Kong demonstrated that pyrazinamide users with documented pyrazinamide susceptibility were more likely to have treatment success compared to non-pyrazinamide users and pyrazinamide users with pyrazinamide-resistant organisms 40 . In Peru, a 2015 retrospective study demonstrated that there was no benefit of pyrazinamide when the drug was unlikely to be effective 41 . Several studies demonstrated better outcomes with respect to mortality rates, treatment success, recurrent TB, and rates of sputum conversion in patients who received at least five likely effective drugs compared to four likely effective drugs [42] [43] [44] [45] [46] . Given these findings, the WHO updated the number of likely effective drugs in the intensive phase from four to five. When pyrazinamide resistance is documented, pyrazinamide may be discontinued and additional drugs, from group C or D, may be added to bring the total to five.
1) Applicability in South Korea
The new Korean guideline updates the number of effective drugs in intensive phase in accordance with the 2016 WHO guideline, but maintains previous recommendation on the composition of MDR-TB regimen 39 . The new Korean guideline recommends that the MDR-TB regimen should be composed of at least five anti-TB drugs that are likely to be effective during the intensive phase. The MDR-TB regimen should include at least pyrazinamide, a fluoroquinolone, an injectable anti-TB drug, prothionamide and either cycloserine or PAS.
Shorter MDR-TB treatment regimen
A shorter MDR-TB treatment regimen, called the Bangladeshi regimen, demonstrated promising results in an observational cohort study in Bangladesh. The relapse-free cure rate was 87.9% in a cohort of 206 MDR-TB patients 47 and 84.4% in an expanded cohort of 515 MDR-TB patients 48 . To verify the reproducibility and generalizability of the Bangladeshi regimen, the WHO and International Union Against Tuberculosis and Lung Disease conducted two approaches in parallel. The first is conducting prospective cohort studies in Africa and Asia. The second is conducting a prospective randomized study, STREAM 1. Recruitment to STREAM 1 was completed in 2015 and results are expected early in 2018. Pilot studies in Niger 49 and Cameroon 50 , with minor modification of the Bangladeshi regimen, also demonstrated consistently high cure rates. The WHO proceeded with the evidentiary assess- . Based on this analysis, the WHO now recommends the shorter MDR-TB regimen as a general strategy for MDR-TB treatment.
The shorter MDR-TB regimen recommended by the WHO consists of a 4-6-month intensive phase with kanamycin, moxifloxacin, ethionamide, clofazimine, pyrazinamide, highdose isoniazid, ethambutol, and a 5-month continuation phase with moxifloxacin, clofazimine, pyrazinamide, and ethambutol. This differs slightly from the Bangladeshi regimen because gatifloxacin has been replaced by moxifloxacin. Notably, the dose of moxifloxacin is higher than the standard dose. The recommended drug dosages for the shorter MDR-TB regimen are shown in Table 2 51 .
4-6 Km
There is a risk for acquiring further drug-resistance if the shorter regimen is used on patients who are already resistant to the core second-line drugs. To avoid this, the WHO provided strict eligibility criteria for the shorter MDR-TB regimen 52 . The shorter regimen is recommended for patients with RR-TB or MDR-TB who were not previously treated with secondline drugs and do not have resistance to fluoroquinolones and second-line injectable drugs. The WHO also recommends the use of a novel molecular test (MTBDRsl test) for eligibility screening 52 , which detects resistance to fluoroquinolones and second-line injectable drugs. However, in the absence of novel molecular testing, patients who are highly unlikely to be infected with resistant strains based on their history of exposure and recent representative surveillance data may also be eligible for the shorter MDR-TB regimen.
1) Applicability in South Korea
There are several concerns about the effectiveness of the shorter regimen in South Korea. One major concern is that the additional drug resistance rate in MDR-TB patients is high in South Korea. High levels of drug resistance in South Korea have been reported in several retrospective MDR-TB cohort studies. Additional resistance to pyrazinamide, ofloxacin, and kanamycin was 26.2%-59%, 16.6%-47.5%, and 13.3%-25%, respectively 3, [8] [9] [10] [11] . A recent regional survey of drug resistance in South Korea demonstrated that strains from MDR-TB patients had additional resistance to pyrazinamide (35 57, 58 . It may be challenging to implement the shorter MDR-TB regimen in the countries with high levels of drug resistance.
Favorable treatment outcomes with the shorter MDR-TB regimen were observed in the studies within operational research conditions. However, directly observed therapy is not implemented and the patient management system is still weak in South Korea. In a large retrospective MDR-TB cohort study in 2008, the default rate was 32% 9 . The number of drugs in the shorter regimen is more than that of conventional regimen. A man weighing ≥50 kg would take 23 tablets and 1 injectable drug each day. Skin pigmentation, an expected side effect of clofazimine, could be occurred in almost all Korean patients. A large number of pills and expected side effect may cause intolerance and subsequently poor treatment adherence. Although the shorter regimen is a tolerable, safe, and patient-friendly regimen in other settings, there are concerns about tolerance and adherence due to the weak patient management system in South Korea. For these reasons, the new Korean guideline suggests that the shorter regimen is not a general strategy for MDR-TB treatment in South Korea but can be used in selected patients 39 .
Conclusion
Previously, diagnosis of MDR-TB was largely dependent upon phenotypic, culture-based methods and the majority of MDR-TB patients received the conventional regimen for a minimum of 20 months. The 2016 WHO guidelines suggest that a paradigm shift is underway and we are at a turning point in MDR-TB management. This shift has centered largely on rapid diagnosis and effective treatment through the use of novel rapid diagnostic tests and a shorter treatment regimen. These changes are welcome, but there are some controversial challenges to adopting the 2016 WHO guidelines in South Korea. The key concerns are the applicability of the new classifications of anti-TB drugs and the shorter MDR-TB regimen in South Korea. Current controversies regarding the 2016 WHO guidelines could be resolved with further evidence from ongoing and future studies.
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